Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Biofrontera ( (DE:B8FK) ) has shared an update.
Biofrontera AG has scheduled the publication of its annual report for the 2025 financial year, covering the period from 1 January to 31 December 2025, for release on 17 April 2026 via its investor relations website. The announcement signals the upcoming disclosure of detailed financial and operational performance data, which will provide shareholders and market participants with key insights into the company’s progress and outlook.
More about Biofrontera
Biofrontera AG is a Germany-based biopharmaceutical company listed on regulated markets in Düsseldorf and Frankfurt, with additional trading venues in Munich, Stuttgart and Tradegate. The company focuses on developing and marketing dermatological drugs, particularly for the treatment of skin diseases, and targets both domestic and international investors through its financial communications.
Average Trading Volume: 1,396
Technical Sentiment Signal: Strong Sell
Current Market Cap: €15.37M
For an in-depth examination of B8FK stock, go to TipRanks’ Overview page.